NCCN task force report: Management of patients with Gastrointestinal Stromal Tumor (GIST) - Update of the NCCN clinical practice guidelines

JNCCN Journal of the National Comprehensive Cancer Network

Volumn 5, Issue SUPPL. 2, 2007, Pages

  Demetri, George D ^a   Benjamin, Robert S ^b   Blanke, Charles D ^c   Blay, Jean Yves ^d   Casali, Paolo ^e   Choi, Haesun ^b   Corless, Christopher L ^c   Debiec Rychter, Maria ^f   DeMatteo, Ronald P ^g   Ettinger, David S ^h   Fisher, George A ⁱ   Fletcher, Christopher D M ^a   Gronchi, Alessandro ^e   Hohenberger, Peter ^j   Hughes, Miranda ^k   Joensuu, Heikki ^l   Judson, Ian ^m   Le Cesne, Axel ⁿ   Maki, Robert G ^g   Morse, Michael ^o   Pappo, Alberto S ^p   Pisters, Peter W T ^b   Raut, Chandrajit P ^a   Reichardt, Peter ^q   Tyler, Douglas S ^r   Van Den Abbeele, Annick D ^a   Von Mehren, Margaret ^s   Wayne, Jeffrey D ^t   Zalcberg, John ^u   more..

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d UNIVERSITÉ LYON 1   (France)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ STANFORD CANCER INSTITUTE   (United States)

^j UNIVERSITY OF HEIDELBERG   (Germany)

^k National Comprehensive Cancer Network   (United States)

^l HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^m ROYAL MARSDEN HOSPITAL   (United Kingdom)

ⁿ INSTITUT GUSTAVE ROUSSY   (France)

^o DUKE CANCER INSTITUTE   (United States)

^p TEXAS CHILDREN S CANCER CENTER   (United States)

^q CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^r DUKE UNIVERSITY MEDICAL CENTER   (United States)

^s FOX CHASE CANCER CENTER   (United States)

^t NORTHWESTERN UNIVERSITY   (United States)

^u PETER MACCALLUM CANCER CENTRE   (Australia)

more..

Author keywords

Abdominal tumor; CD117; Gastric mass; Gastrointestinal stromal tumor; Gastrointestinal tract; GIST; Imatinib; KIT; Liver metastasis; NCCN Clinical Practice Guidelines; Sarcoma; Small bowel tumor; Stomach cancer; Sunitinib; Tyrosine kinase

Indexed keywords

ALPRAZOLAM; AMLODIPINE; ANTACID AGENT; APREPITANT; ATROPINE; CARBAMAZEPINE; CLARITHROMYCIN; CYCLOSPORIN; CYCLOSPORIN A; DEXAMETHASONE; DIPHENHYDRAMINE; ERYTHROMYCIN; IMATINIB; ITRACONAZOLE; KETOCONAZOLE; LEVOTHYROXINE; LEVOTHYROXINE SODIUM; LOPERAMIDE; NIFEDIPINE; NITRENDIPINE; PARACETAMOL; PHENOBARBITAL; PHENYTOIN; PIMOZIDE; PLACEBO; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SIMVASTATIN; SUNITINIB; WARFARIN; BENZAMIDE DERIVATIVE; INDOLE DERIVATIVE; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ABSCESS; ANEMIA; ANOREXIA; AUSTRALIA; BLEEDING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CLINICAL TRIAL; DIAGNOSTIC PROCEDURE; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPEPSIA; EUROPE; FATIGUE; FLUID RETENTION; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HISTOPATHOLOGY; HUMAN; HYPERTENSION; HYPOTHYROIDISM; INTESTINE OBSTRUCTION; LOOSE FECES; MUCOSA INFLAMMATION; MUSCLE CRAMP; NAUSEA; NEUTROPENIA; ONCOLOGY; PATIENT CARE; PRACTICE GUIDELINE; RASH; REVIEW; SIDE EFFECT; SKIN DISCOLORATION; UNITED STATES; VOMITING; ADVISORY COMMITTEE; COMPUTER ASSISTED TOMOGRAPHY; EPIDEMIOLOGY; GASTROINTESTINAL STROMAL TUMORS; IMMUNOHISTOCHEMISTRY; PATHOLOGY; PROGNOSIS;

ADVISORY COMMITTEES; BENZAMIDES; GASTROINTESTINAL STROMAL TUMORS; HUMANS; IMMUNOHISTOCHEMISTRY; INDOLES; PIPERAZINES; PRACTICE GUIDELINES AS TOPIC; PROGNOSIS; PYRIMIDINES; PYRROLES; TOMOGRAPHY, X-RAY COMPUTED; UNITED STATES;

EID: 34447557780     PISSN: 15401405     EISSN: 15401413     Source Type: Journal    
DOI: None     Document Type: Review

References (119)

1. Nishida T, Hirota S. Biological and clinical review of stromal tumors in the gastrointestinal tract. Histol Histopathol 2000;15: 1293-1301.
2. Thomas RM, Sobin LH. Gastrointestinal cancer. Cancer 1995; 75:154-170.
3. Tran T, Davila J A, El-Serag HB. The epidemiology of malignant gastrointestinal stromal tumors: an analysis of 1,458 cases from 1992 to 2000. Am J Gastroenterol 2005;100:162-168.
4. Tryggvason G, Gislason HG, Magnusson MK, et al. Gastrointestinal stromal tumors in Iceland, 1990-2003: the Icelandic GIST study, a population-based incidence and pathologic risk stratification study. Int J Cancer 2005;117:289-293.
5. Goettsch WG, Bos SD, Breekveldt-Postma N, et al. Incidence of gastrointestinal stromal tumors is underestimated: results of a nation-wide study. Eur J Cancer 2005;41:2868-2872.
6. Rubio J, Marcos-Gragera R, Ortiz MR, et al. Population-based incidence and survival of gastrointestinal stromal tumors (GIST) in Girona, Spain. Eur J Cancer 2007;43:144-148.
7. Nilsson B, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era - a population-based study in western Sweden. Cancer 2005;103:821-829.
8. Agaimy A, Wunsch PH, Hofstaedter F, et al. Minute gastric sclerosing stromal tumors (GIST tumorlets) are common in adults and frequently show c-KIT mutations. Am J Surg Pathol 2007;31: 113-120.
9. Kawanowa K, Sakuma Y, Sakurai S, et al. High incidence of microscopic gastrointestinal stromal tumors in the stomach. Hum Pathol 2006;37:1527-1535.
10. Miettinen M, Sobin LH, Lasota J. Gastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol 2005;29:52-68.
11. Miettinen M, Makhlouf H, Sobin LH, et al. Gastrointestinal stromal tumors of the jejunum and ileum: a clinicopathologic, immunohistochemical, and molecular genetic study of 906 cases before imatinib with long-term follow-up. Am J Surg Pathol 2006;30: 477-489.
12. Perez EA, Livingstone AS, Franceschi D, et al. Current incidence and outcomes of gastrointestinal mesenchymal tumors including gastrointestinal stromal tumors. J Am Coll Surg 2006;202:623-629.
13. Steigen SE, Eide TJ. Trends in the incidence and survival of mesenchymal neoplasm of the digestive tract within a defined population of northern Norway. APMIS 2006;114:192-200.
14. Emory TS, Sobin LH, Lukes L, et al. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999;23:82-87.
15. Reith JD, Goldblum JR, Lyles RH, Weiss SW. Extragastrointestinal (soft tissue) stromal tumors: an analysis of 48 cases with emphasis on histologic predictors of outcome. Mod Pathol 2000;13:577-585.
16. DeMatteo RP, Lewis JJ, Leung D, et al. Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg 2000;231:51-58.
17. Miettinen M, Lasota J. Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin Diagn Pathol 2006;23:70-83.
18. Fletcher C, Berman J, Corless C, et al. Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol 2002;33: 459-465.
19. Dow N, Giblen G, Sobin LH, et al. Gastrointestinal stromal tumors: differential diagnosis. Semin Diagn Pathol 2006;23:111-119.
20. Chirieac LR, Trent JC, Steinert DM, et al. Correlation of immunophenotype with progression-free survival in patients with gastrointestinal stromal tumors treated with imatinib mesylate. Cancer 2006;107:2237-2244.
21. Debiec-Rychter M, Wasag B, Stul M, et al. Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity. J Pathol 2004;202:430-438.
22. Medeiros F, Corless CL, Duensing A, et al. KIT-negative gastrointestinal stromal tumors: proof of concept and therapeutic implications. Am J Surg Pathol 2004;28:889-894.
23. Duensing A, Joseph NE, Medeiros F, et al. Protein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs). Cancer Res 2004;64:5127-5131.
24. Peterson MR, Piao Z, Weidner N, Yi ES. Strong PDGFRA positivity is seen in GISTs but not in other intra-abdominal mesenchymal tumors: immunohistochemical and mutational analyses. Appl Immunohistochem Mol Morphol 2006;14:390-396.
25. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol 2004;165: 107-113.
26. Miettinen M, Lasota J. Gastrointestinal stromal tumors - definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001;438:1-12.
27. Corless CL, Fletcher JA, Heinrich MC. Biology of gastrointestinal stromal tumors. J Clin Oncol 2004;22:3813-3825.
28. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 2006;130:1466-1478.
29. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 2003; 299:708-710.
30. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-667.
31. Singer S, Rubin BP, Lux ML, et al. Prognostic value of KIT mutation type, mitotic activity, and histologic subtype in gastrointestinal stromal tumors. J Clin Oncol 2002;20:3898-3905.
32. Kim TW, Lee H, Kang YK, et al. Prognostic significance of c-kit mutation in localized gastrointestinal stromal tumors. Clin Cancer Res 2004;10:3076-3081.
33. Andersson J, Bumming P, Meis-Kindblom JM, et al. Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis. Gastroenterology 2006;130:1573-1581.
34. Martin J, Poveda A, Llombart-Bosch A, et al. Deletions affecting codons 557-558 of the c-KIT gene indicate a poor prognosis in patients with completely resected gastrointestinal stromal tumors: a study by the Spanish Group for Sarcoma Research (GEIS). J Clin Oncol 2005;23:6190-6198.
35. Corless CL, McGreevey L, Haley A, et al. KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. Am J Pathol 2002;160:1567-1572.
36. Antonescu CR, Sommer G, Sarran L, et al. Association of KIT exon 9 mutations with non-gastric primary site and aggressive behaviour: KIT mutation analysis and clinical correlates of 120 gastrointestinal stromal tumors. Clin Cancer Res 2003;9:3329-3337.
37. Lasota J, Kopczynski J, Sarlomo-Rikala M, et al. KIT 1530ins6 mutation defines a subset of predominantly malignant gastrointestinal stromal tumors of intestinal otigin. Hum Pathol 2003;34:1306-1312.
38. Lasota J, Dansonka-Mieszkowska A, Sobin LH, et al. A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential. Lab Invest 2004;84:874-883.
39. Lasota J, Stachura J, Miettinen M. GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology. Lab Invest 2006;86:94-100.
40. Heinrich MC, Griffith DJ, Druker BJ, et al. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000;96:925-932.
41. Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exper Thera 2000;295:139-145.
42. Tuveson DA, Willis NA, Jacks T, et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications. Oncogene 2001;20:5054-5058.
43. Prenen H, Cools J, Mentens N, et al. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate. Clin Cancer Res 2006;12: 2622-2627.
44. Heinrich MC, Corless CL, Demetri GD, et al. Kinase mutations and imatinib mesylate response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol 2003;21:4342-4349.
45. Debiec-Rychter M, Sciot R, Le Cesne A, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur J Cancer 2006;42:1093-1103.
46. Miettinen M, Lasota J, Sobin LH. Gastrointestinal stromal tumors of the stomach in children and young adults. Am J Surg Pathol 2005;29:1373-1381.
47. Prakash S, Sarran L, Socci N, et al. Gastrointestinal stromal tumors in children and young adults. J Pediatr Hematol Oncol 2005; 27:179-187.
48. Janeway KA, Matthews DC, Butrynski JE, et al. Sunitinib treatment of pediatric metastatic GIST after failure of imatinib [abstract]. J Clin Oncol 2006;24(suppl 1):524s. Abstract 9519.
49. Blanke CD, Corless CL. State-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest 2005;23:274-280.
50. Demetri G, von Mehren M, Blanke C, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
51. Ryan DP, Puchalski T, Supko JG, et al. A phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist 2002;7:531-538.
52. Edmonson JH, Marks RS, Buckner JC, et al. Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. Cancer Invest 2002;20:605-612.
53. Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med 1996;2:561-566.
54. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 1998;279:577-580.
55. Rubin BP, Singer S, Tsao C, et al. KIT activation is a ubiquitous feature of gastrointestinal stromal tumors. Cancer Res 2001;61: 8118-8121.
56. Joensuu H, Roberts PJ, Sarlomo-Rikala M, et al. Effect of the tyrosine kinase inhibitor STI 571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001;344:1052-1056.
57. von Mehren M, Blanke C, Joensuu H, et al. High incidence of durable responses induced by imatinib mesylate (Gleevec) in patients with unresectable and metastatic gastrointestinal stromal tumors (GISTs) [abstract]. Proc Am Soc Clin Oncol 2002;21:403a. Abstract 1608.
58. Dagher R, Cohen M, Williams G, et al. Approval summary: imatinib mesylate in the treatment of metastatic and/or unresectable malignant gastrointestinal stromal tumors. Clin Cancer Res 2002;8:3034-3038.
59. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004;364:1127-1134.
60. Rutkowski P, Nowecki Z, Nyckowski P, et al. Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J Surg Oncol 2006;93:304-311.
61. van Oosterom A, Judson I, Verweij J, et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-1423.
62. Verweij J, van Oosterom A, Blay J, et al. Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Eur J Cancer 2003;39:2006-2011.
63. Benjamin RS, Rankin C, Fletcher C, et al. Phase III dose-randomized study of imatinib mesylate (STI 571) for GIST: Intergroup S0033 early results [abstract]. Proc Am Soc Clin Oncol 2003;22:814. Abstract 3271.
64. Dileo P, Rankin CJ, Benjamin RS, et al. Incidence and reasons for dose modification of standard-dose vs. high-dose imatinib mesylate (IM) in the phase III Intergroup Study S0033 of patients (pts) with unresectable or metastatic gastrointestinal stromal tumor (GIST) [abstract]. J Clin Oncol 2005;23(suppl 1):824s. Abstract 9032.
65. Ferrero D, Pogliani EM, Rege-Cambrin G, et al. Corticosteroids can reverse severe imatinib-induced hepatotoxicity. Haematologica 2006;91(6 Suppl):ECR27.
66. van Oosterom A, Judson I, Verweij J, et al. Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 2002;38(suppl 5):S83-S87.
67. Berman E, Nicolaides M, Maki RG, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-2013.
68. Joensuu H, Reichardt P. Imatinib and altered bone and mineral metabolism [letter]. N Engl J Med 2006;355;627-628.
69. Kerkela R, Grazette L, Yacobi R, et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Med 2006;12:881-882.
70. Frye RF, Fitzgerald SM, Lagattuta TF, et al. Effect of St John's wort on imatinib mesylate pharmacokinetics. Clin Pharmacol Ther 2004; 76:323-329.
71. Dutreix C, Peng B, Mehring G, et al. Pharmacokinetic interaction between ketoconazole and imatinib mesylate (Glivec) in healthy subjects. Cancer Chemother Pharmacol 2004;54:290-294.
72. de Groot JW, Zonnenberg BA, Plukker JT, et al. Imatinib induces hypothyroidism in patients receiving levothyroxine. Clin Pharmacol Ther 2005;78:433-438.
73. Bolton AE, Peng B, Hubert M, et al. Effect of rifampicin on the pharmacokinetics of imatinib mesylate (Gleevec, STI571) in healthy subjects. Cancer Chemother Pharmacol 2004;53: 102-106.
74. O'Brien SG, Meinhardt P, Bond E, et al. Effects of imatinib mesylate (STI571, Glivec) on the pharmacokinetics of simvastatin, a cytochrome P450 3A4 substrate, in patients with chronic myeloid leukaemia. Br J Cancer 2003;89:1855-1859.
75. Hidaka M, Okumura M, Fujita K, et al. Effects of pomegranate juice on human cytochrome p450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos 2005;33:644-648.
76. Le Cesne A, Van Glabbeke M, Verweij J, et al. Is a stable disease according to RECIST criteria a real stable disease in GIST patients treated with imatinib mesylate (IM) included in the intergroup EORTC/ISG/AGITG trial? J Clin Oncol 2006;24(suppl 1):522s. Abstract 9510.
77. Kindblom LG, Meis-Kindblom J, Bumming P, et al. Incidence, prevalence, phenotype and biologic spectrum of gastrointestinal stromal tumors (GIST) - a population-based study of 600 cases [abstract]. Ann Oncol 2003;13. Abstract 157.
78. Blanke CD, Demetri GD, von Mehren M, et al. Long-term follow-up of a phase II randomized trial in advanced GIST patients treated with imatinib mesylate [abstract]. J Clin Oncol 2006;24:526s. Abstract 9526.
79. Heinrich MC, Corless CL, Blanke CD, et al. Molecular correlates of imatinib resistance in gastrointestinal stromal tumors. J Clin Oncol 2006;24:4764-4774.
80. Debiec-Rychter M, Cools J, Dumez H, et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005;128:270-279.
81. Chen LL, Trent JC, Wu EF, et al. A missense mutation in KIT kinase domain 1 correlates with imatinib resistance in gastrointestinal stromal tumors. Cancer Res 2004;64:5913-5919.
82. Antonescu CR, Besmer P, Guo T, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res 2005;11:4182-4190.
83. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 2006;368:1329-1338.
84. Desai J, Yassa L, Marqusee E, et al. Hypothyroidism after sunitinib treatment for patients with gastrointestinal stromal tumors. Ann Intern Med 2006;145:660-664.
85. Fong Y, Coit DG, Woodruff JM, et al. Lymph node metastasis from soft tissue sarcoma in adults. Analysis of data from a prospective database of 1772 sarcoma patients. Ann Surg 1993;217:72-77.
86. Davila RE, Faigel DO. GI stromal tumors. Gastrointest Endosc 2003;58:80-88.
87. Otani Y, Kitajima M. Laparoscopic surgery: too soon to decide. Gastric Cancer 2005;8:135-136.
88. Novitsky YW, Kercher KW, Sing RF, et al. Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors. Ann Surg 2006;243:738-745; discussion 745-747.
89. Otani Y, Furukawa T, Yoshida M, et al. Operative indications for relatively small (2-5 cm) gastrointestinal stromal tumor of the stomach based on analysis of 60 operated cases. Surgery 2006;139:484-492.
90. Ng EH, Pollock RE, Munsell MF, et al. Prognostic factors influencing survival in gastrointestinal leiomyosarcomas. Implications for surgical management and staging. Ann Surg 1992;215:68-77.
91. Akwari OE, Dozois RR, Weiland LH, et al. Leiomyosarcoma of the small and large bowel. Cancer 1978;42:1375-1384.
92. McGrath PC, Neifeld JP, Lawrence WJ, et al. Gastrointestinal sarcomas. Analysis of prognostic factors. Ann Surg 1987;206:706-710.
93. Bonvalot S, Eldweny H, Pechoux CL, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol 2006;13:1596-1603.
94. DeMatteo RP, Antonescu CR, Chadaram V, et al. Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the U.S. Intergroup Phase II trial ACOSOG Z9000. J Clin Oncol 2005;23(suppl 1):818s. Abstract 9009.
95. Ng EH, Pollock RE, Romsdahl MM. Prognostic implications of patterns of failure for gastrointestinal leiomyosarcomas. Cancer 1992;69:1334-1341.
96. Scaife CL, Hunt KK, Patel SR, et al. Is there a role for surgery in patients with "unresectable" cKIT+ gastrointestinal stromal tumors treated with imatinib mesylate? Am J Surg 2003;186:665-669.
97. Bumming P, Andersson J, Meis-Kindblom JM, et al. Neoadjuvant, adjuvant and palliative treatment of gastrointestinal stromal tumours (GIST) with imatinib: a centre-based study of 17 patients. Br J Cancer 2003;89:460-464.
98. Bauer S, Hartmann JT, de Wit M, et al. Resection of residual disease in patients with metastatic gastrointestinal stromal tumors responding to treatment with imatinib. Int J Cancer 2005;117: 316-325.
99. Raut CP, Posner M, Desai J, et al. Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J Clin Oncol 2006;24: 2325-2331.
100. Andtbacka RH, Ng CS, Scaife CL, et al. Surgical resection of gastrointestinal stromal tumors after treatment with imatinib. Ann Surg Oncol 2007;14:14-24.
101. Hohenberger P, Langer C, Pistorius S, et al. Indication and results of surgery following imatinib treatment of locally advanced or metastatic GI stromal tumors (GIST) [abstract]. J Clin Oncol 2006;24(suppl 1):520s. Abstract 9500.
102. Gronchi A, Fiore M, Miselli F, et al. Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST. Ann Surg 2007;245:341-346.
103. DeMatteo RP, Maki RG, Singer S, et al. Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor (GIST). Ann Surg 2007;245:347-352.
104. Maluccio MA, Covey AM, Schubert J, et al. Treatment of metastatic satcoma to the liver with bland embolization. Cancer 2006; 107:1617-1623.
105. Kobayashi K, Gupta S, Trent JC, et al. Hepatic artery chemoembolization for 110 gastrointestinal stromal tumors: response, survival, and prognostic factors. Cancer 2006;107:2833-2841.
106. Choi HC, Macapinlac HA, Burgess MA, et al. Cotrelation of computerized tomography (CT) and proton emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate. Proc Am Soc Clin Oncol 2003;22:819. Abstract 3290.
107. Choi H, Charnsangavej C, Faria SC, et al. Correlation of computed tomography (CT) and positron emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate: proposal of new CT response criteria. J Clin Oncol 2007;25:1753-1759.
108. Choi H, Charnsangavej C, Faria SC, et al. CT evaluation of the response of gastrointestinal stromal tumors after imatinib mesylate treatment: a quantitative analysis correlated with FDG PET findings. Am J Roentgenol 2004;183:1619-1628.
109. Benjamin RS, Choi H, Macapinlac HA, et al. We should desist using RECIST, at least in GIST. J Clin Oncol 2007;25:1760-1764.
110. Holdsworth CH, Manola J, Badawi RD, et al. Use of computerized tomography (CT) as an early prognostic indicatot of response to imatinib mesylate (IM) in patients with gastrointestinal stromal tumors (GIST) [abstract]. J Clin Oncol 2004;22:Abstract 3011.
111. Van den Abbeele AD, Badawi RD, Cliche JP, et al. Response to imatinib mesylate (Gleevec™) therapy in patients with advanced gas-trointestinal stromal tumors (GIST) is demonstrated by F-18-FDG-PET prior to anatomic imaging with CT. Radiology 2002;225:424P.
112. Shankar S, vanSonnenberg E, Desai J, et al. Gastrointestinal stromal tumor: new nodule-widain-a-mass pattern of recurrence after partial response to imatinib mesylate. Radiology 2005;235:892-898.
113. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002;38(Suppl 5):S60-S65.
114. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. Eur J Cancer 1999;35: 1773-1782.
115. Blodgett TM, Meltzer CC, Townsend DW. PET/CT: form and function. Radiology 2007;242:360-385.
116. Van den Abbeele AD, for the GIST Collaborative PET Study Group. F18-FDG-PET provides early evidence of biological response to STI571 in patients with malignant gastrointestinal stromal tumors (GIST) [abstract]. Proc Am Soc Clin Oncol 2001;20: 362a. Abstract 1444.
117. 18F-FDG-PET predicts response to imatinib mesylate (Gleevec) in patients with advanced gastrointestinal stromal tumors (GIST) [abstract]. Proc Am Soc Clin Oncol 2002;21:403a. Abstract 1610.
118. Van den Abbeele AD, Badawi RD, Cliche JP, et al. FDG-PET as a surrogate marker for the response to Gleevec (imatinib mesylate) in patients with advanced gastrointestinal stromal tumors (GIST). J Nucl Med 2003;44:24P-25P.
119. Van den Abbeele AD, Badawi RD, Manola J, et al. Effects of cessation of imatinib mesylate (IM) therapy in patients (pts) with IM-refractory gastrointestinal stromal tumors (GIST) as visualized by FDG-PET scanning [abstract]. J Clin Oncol 2004;22(14 suppl): Abstract 3012.